Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-151P belongs to a large family of U1 small nuclear RNA pseudogenes distributed throughout the human genome[7][8]. U1 snRNA is an indispensable component of the spliceosome responsible for pre-mRNA splicing, but pseudogenes like RNU1-151P contain incomplete or imperfect versions of this RNA. While some U1 snRNA pseudogenes may be transcriptionally active and produce variant RNAs with potential regulatory roles[3][7], there is no evidence that RNU1-151P itself has an established function or serves as a therapeutic target. Generally, such pseudogenes are not considered viable drug targets, nor are they used as disease biomarkers or associated with particular safety issues.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 151, pseudogene (RNU1-151P).